Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | ITGAL | P20701 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985287 | 0.86 | ITGB1 (0.54) | POLBITGB1ITGA4ITGB7CA1 | |
| SCHEMBL6606096 | 0.85 | CASP3 (0.55) | PYGLPOLBGPR139 | |
| SCHEMBL28797504 | 0.85 | PYGL (0.54) | PYGLPOLBITGB1ITGA4ITGB7 | |
| SCHEMBL26263222 | 0.84 | ITGB1 (0.56) | POLBITGB1ITGA4ITGB7GPR139 | |
| SCHEMBL2789470 | 0.84 | ITGB1 (0.56) | POLBITGB1ITGA4ITGB7GPR139 | |
| SCHEMBL16993943 | 0.83 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL16993942 | 0.83 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL22983957 | 0.83 | ITGB2 (0.64) | PYGLITGB1ITGA4ITGB7CA1 | |
| SCHEMBL22983958 | 0.83 | ITGB2 (0.64) | PYGLITGB1ITGA4ITGB7CA1 | |
| SCHEMBL18277717 | 0.83 | KDM4E (0.54) | PYGLCA1CA2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183776-A2 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | PYGL 3933/4885POLB 4570/4885ITGB1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.